Disease Landscape and Forecast 인사이트

In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that leverage their internal capability and potentially capture the expertise of…

Myelodysplastic syndromes (MDS) consists of a group of disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis and deteriorating…

In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States…

In the Highly Genericized Insomnia Market, What Opportunities Remain for New Therapies? We expect the prevalence of insomnia in the seven major pharmaceutical markets under study (United States…

In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…

In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…

What Untapped Opportunities Remain for the Treatment of Genotype-3 Infections? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) is a serious public health crisis…

Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing…

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing…

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib…